GELS
Gelteq Limited
Healthcare — Drug Manufacturers - Specialty & Generic
Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.
None
$0.52
$-0.01 (-1.36%)
Price History
52-Week Range
Sign in to add GELS to a watchlist or set price alerts.
Fundamentals
| Market Cap | $7.07M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-0.50 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | -43.10% |
| ROE | -42.93% |
| Debt/Equity | 36.01 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 52.9 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $2.02 |
| 52-Week Low | $0.39 |
| 50-Day Avg | $0.63 |
| 200-Day Avg | $0.89 |
| Avg Volume | $3.76M |
| Volume | 24.7K |
Performance Analysis
NEUTRALGELS presents a mixed picture with both positive and negative indicators.
+
Trading near its 52-week low ($0.39), which could present a value opportunity.
~
RSI at 52.9 is in neutral territory.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
-
Revenue declined 43.1% year-over-year.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:11 UTC
Back to Screener Export Report